About us

APIM Therapeutics AS is a venture-capital financed biotech spin-off from the Norwegian University of Science and Technology (NTNU, Trondheim).

Based on an original discovery by Prof. Marit Otterlei and co-inventors, the company targets a novel therapeutic intervention point shown to be critical in the regulation of cellular responses to stress and in tumor evasion from therapy.

about us inner img

Briefly, APIM Therapeutics is using a series of proprietary Protein Protein Interaction (PPI) blocking peptides targeting complexes formed between PCNA (Proliferating Cell Nuclear Antigen) and proteins bearing a novel PCNA-interacting Peptide Motif called APIM (AlkB homolog 2 PCNA Interacting Motif). A series of preclinical and other experiments have revealed the functional importance of PCNA/APIM-protein interactions in the regulation of cancer cell growth and apoptosis e.g. during DNA Damage Response (DDR) induced by anti-cancer treatment. Furthermore, it was shown that cell penetrating peptides containing the APIM-motif abrogate PCNA-APIM protein interactions and are capable of potentiating the action of several classes of anti-cancer drugs across multiple indications.

APIM’s lead therapeutic candidate ATX-101, is a first-in class compound targeting this intervention point that has recently reached the clinical stage. In preclinical experiments, ATX-101 has shown single agent activity in blood cancer and combinatorial activity with more than 25 different anti-cancer drugs in different tumor indications. Developed as a new therapeutic option for myeloma and bladder cancer, ATX-101 is currently being tested in a phase I study in advanced cancer patients. The study is being conducted by APIM’s fully owned subsidiary Therapim Pty Ltd.

For more information on our technology, please see Intervention Point, ATX-101 and Publications. An 1-page flyer providing key company & technology highlights is also available here.